Prostate Cancer

When Should Men Begin (and Stop) Prostate Cancer Screening?

Frank dela Rama explains the current recommendations for screening for prostate cancer.
Video Library – March 6, 2019
Frank dela Rama, RN, MS, AOCNS
Clinical Nurse Specialist, Oncology/Genomics
CANCER CARE Palo Alto Medical Foundation
Palo Alto, CA
Frank dela Rama explains the current recommendations for screening for prostate cancer.

Share this:

Recommended For You
Prostate Cancer
Lynparza Improves Quality of Life in Men with Metastatic Prostate Cancer
By Meg Barbor, MPH
The PARP inhibitor Lynparza (olaparib), a type of drug that is usually used for the treatment of women with ovarian cancer, has also been studied in men with prostate cancer. The results of the PROfound clinical trial were recently presented at the 2020 ASCO annual meeting by Antoine Thiery-Vuillemin, MD, PhD, Centre Hospitalier de Besançon, France.
Prostate Cancer
The Combination of Cabometyx plus Tecentriq Improves Outcomes in Patients with Advanced Prostate Cancer
By Meg Barbor, MPH
Results of a new study showed that the combination of Cabometyx (cabozantinib) and the immune checkpoint inhibitor Tecentriq (atezolizumab) was safe and effective in men with metastatic (spreading) castration-resistant prostate cancer, the most common type of prostate cancer.
Prostate Cancer
Drugs for Prostate Cancer
Here are the drugs and financial support services available to patients receiving treatment for Prostate Cancer.
Patient AdvocacyPatient StoriesProstate Cancer
You Are Perfectly Healthy, It’s Just the “Good Cancer”
By Dennis E. Golden
Dennis Golden was an active, fit, 70-year-old when he learned he had prostate cancer. He was surprised to discover that few men know the warning signs and how potentially serious it can be. In response, he formed the National Prostate Cancer Awareness Foundation to educate men about this disease.
Last modified: March 19, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.